原发性免疫性血小板减少症患者因糖代谢异常导致T细胞功能障碍
研究原发免疫性血小板减少症(ITP)患者T细胞糖代谢异常及mTORC1在调节性T细胞(Treg)抑制功能中的作用。ITP患者Treg和效应T细胞(Teff)的细胞外酸化率(ECAR)均升高,糖皮质激素治疗后Teff的ECAR恢复正常而Treg仍高于正常;抑制mTORC1可恢复ITP Treg的抑制功能。
要点
- ITP患者Treg和Teff的ECAR均升高,糖皮质激素治疗后Teff的ECAR恢复正常,Treg的ECAR下降但仍高于正常水平。
- ITP患者Treg和Teff的GLUT1及p-S6表达显著升高,糖皮质激素治疗后GLUT1水平恢复正常。
- 抑制mTORC1可恢复ITP患者Treg的抑制功能。
核心结论
- CD4+ T细胞糖代谢失调参与ITP发病机制,靶向mTORC1信号可能为ITP提供新的治疗途径。
研究设计与样本
- 对系统性红斑狼疮(SLE)患者功能失调Treg进行基因集富集分析(GSEA),评估糖酵解和mTORC1通路。
- 从外周血单个核细胞(PBMC)中分离CD4+效应T细胞(Teff),来源包括地塞米松治疗前后及健康对照。
- 用Agilent Seahorse XF96平台测定Treg和Teff的细胞外酸化率(ECAR)。
- 用流式细胞术评估葡萄糖转运蛋白1(GLUT1)和磷酸化S6(p-S6)表达。
- 通过mTORC1抑制试验评估Treg的免疫抑制功能。
主要发现
- GSEA显示功能失调Treg中糖酵解与mTORC1信号可能存在关联。
- ITP患者Treg和Teff的ECAR均升高,糖皮质激素治疗后Teff的ECAR恢复正常。
- ITP患者Treg的ECAR在治疗后下降,但仍高于正常水平。
- ITP患者Treg和Teff的GLUT1及p-S6表达显著升高,糖皮质激素治疗后GLUT1水平恢复正常。
- 抑制mTORC1可恢复ITP患者Treg的抑制功能。
临床怎么用
- 作者认为靶向mTORC1信号可能为ITP提供新的治疗途径。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To investigate T-cell glucose metabolism dysfunction in primary immune thrombocytopenia (ITP) and the role of mammalian target of rapamycin complex 1 (mTORC1) in regulatory T-cell (Treg) suppression function. Gene set enrichment analysis (GSEA) assessed glycolysis and mTORC1 pathways in dysfunctional Tregs from patients with systemic lupus erythematosus (SLE). CD4+ effector T cells (Teffs) were isolated from peripheral blood mononuclear cells (PBMCs) pre- and post-dexamethasone treatment and from healthy controls. The extracellular acidification rate (ECAR) of Tregs and Teffs was measured using the Agilent Seahorse XF96 platform. Flow cytometry evaluated glucose transporter 1 (GLUT1) and phosphorylated S6 (p-S6) expression. The immune suppression function of Tregs was assessed by mTORC1 inhibiting test. GSEA revealed a possible relation of glycolysis and mTORC1 signalling in dysfunctional Tregs. Both Tregs and Teffs from ITP patients showed elevated ECAR, with Teff ECAR normalizing post-glucocorticoid treatment. Treg ECAR decreased after treatment, but remained higher than normal level. GLUT1 and p-S6 expression was significantly higher in ITP Tregs and Teffs, normalizing GLUT1 levels after glucocorticoid therapy. Inhibiting mTORC1 could recover the suppression of ITP Tregs. Dysregulated CD4+ T-cell glucose metabolism contributes to ITP pathogenesis. Targeting mTORC1 signal may offer a novel therapeutic approach for ITP.
引用
- Tang M, Li B, Zhuang J, et al. Dysfunctional T cells due to the abnormal glucose metabolism in patients with primary immune thrombocytopenia. Br J Haematol. 2025. PMID: 41201304. doi:10.1111/bjh.70229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。